Company Overview and News

 
Department 13 secures order from Latin American federal prison

2017-10-10 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) has received a purchase order for the sale of two MESMER™ units into a federal prison system in the Latin American region.
Upvote Downvote

 
Department 13 secures U.S. patent, gets ready for 5G mobile

2017-09-20 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) has been issued a patent titled “Pre-coding in multi user MIMO” (multiple-input multiple-output) in the U.S.
Upvote Downvote

 
Department 13 granted U.S. patent to enhance counter drone solution

2017-06-07 proactiveinvestors.com.au
Department 13 (ASX:D13) has been issued a U.S. patent for “Intrusion Detection and Radio Fingerprint Tracking” covering techniques that enhance security over wi-fi and cellular networks.
Upvote Downvote

 
Department 13 International bags $5.5M to meet sales demand

2017-05-04 proactiveinvestors.com.au
Department 13 International (ASX:D13) has received firm commitments from new and existing shareholders to raise $5,543,790 at an issue price of $0.125 per share.
Upvote Downvote

 
Department 13 wins first Australian order for counter drone solution

2017-04-11 proactiveinvestors.com.au
Department 13 (ASX:D13) has crossed a major milestone by securing the first sale of its MESMER counter drone solution to an Australian customer.
Upvote Downvote

 
Department 13 International to outline sales agreement

2017-04-10 proactiveinvestors.com.au
Department 13 International (ASX:D13) has been granted a trading halt by the ASX, pending details of a sales agreement
Upvote Downvote

 
Department 13 International demonstrates counter-drone product

2017-03-13 proactiveinvestors.com.au
Department 13 International (ASX:D13) conducted a series of sales demonstrations and operational tests in Australia of its recently launched flagship counter-drone product, MESMER.
Upvote Downvote

 
Department 13 International Ltd demonstrates counter-drone solution

2016-09-26 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) has successfully demonstrated its counter-drone solution ‘Mesmer’ at Black Dart, a U.S. Department of Defense counter-drone evaluation exercise. The Black Dart event was held at the Eglin Air Force Base in Florida, U.S. Department 13’s Mesmer has the ability to take control of a drone and land it, against the will of the source controller. Over the course of the exercise at Eglin Air Force Base, Mesmer demonstrated this capability with a range in excess of one kilometre.
Upvote Downvote

 
Department 13 International Ltd heads to market

2016-07-25 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) has been granted a trading halt by the ASX, pending details of a capital raising. The halt will remain in place until the opening of trade on Wednesday 27th July 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Department 13 International Ltd to stave off hostile drones in Latin America

2016-07-19 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) has appointed Phoenix Group as the Latin American distributor for its flagship counter-drone technology - MESMER. The Latin American market is a natural landing point for MESMER, as the ability of criminal organisations to disrupt global trade through drones is a threat in this region. The Phoenix Group is a security company that provides security services to transportation companies including the prevention of piracy, stowaways, terrorism, narcotics smuggling and other unique services.
Upvote Downvote

 
Department 13 International Ltd to update on contract

2016-07-12 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) has been granted a trading halt by the ASX, with its shares placed in pre-open. Department 13 requested the halt pending further information concerning the size and operation of the US Navy Research Labs and Parsons Prime Contract and Department 13's sub contract for networking, communications and cyber security services to the US Navy. The halt will remain in place until the opening of trade on Thursday 14th July 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Department 13 International Ltd takes aim at U.S. counter drone market

2016-07-05 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) is an innovative technology company focused on wireless and mobile technologies to create solutions that transform communications, collaboration, and defense.
Upvote Downvote

 
Appendix 3Y G Rezos

2016-05-06 asx.com.au
Upvote Downvote

 
 
Department 13 granted U.S. patent for data transfer technology

2016-04-27 proactiveinvestors.com.au
Department 13 International Ltd (ASX:D13) formerly Kunene Resources is an innovative technology company focusing on wireless and mobile technologies to create solutions that transform communication, collaboration, and defense.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...